The top drug classes advertising in professional health journals through October 2013
Total print advertising dollars in professional health journals reached more than $491 million through October 2013, a 5% decrease year-over-year, according to Kantar Media. The top product class continues to be Cancer Therapy with nearly $39 million spent advertising in professional health journals year-to-date. This class was also ranked first in 2012 and second in 2013. Antipsychotics – Other is a newcomer to the top five this month. Last year at this time, it was ranked #15.
The top product classes by dollars are as follows:
Top 5 Print Ad Drug Classes (Dollars): Jan. – October 2013
- Cancer Therapy Products – $39 MM (+14%)
- Anticoagulants Oral – $23 MM (+33%)
- Diabetes Oral - $15 MM (+203%)
- Diabetes Insulin – $10 MM (-41%)
- Antipsychotics - Other - $8 MM (+141%)
The percentage changes compare January – October 2013 to that same time period in 2012. For more information on these ad insights or other data, let one of us know.
Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in the professional healthcare arena. Check back next month for updated data on the top products, classes, companies and category movers year-to-date.